HIV-associated Lipodystrophy - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "HIV-associated Lipodystrophy - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the HIV-associated Lipodystrophy epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

HIV-associated Lipodystrophy Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for HIV-associated Lipodystrophy in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the HIV-associated Lipodystrophy outlook. It also includes the explanation of changing trends of epidemiology outlining the HIV-associated Lipodystrophy scenario.

HIV-associated Lipodystrophy Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the HIV-associated Lipodystrophy thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of HIV-associated Lipodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The HIV-associated Lipodystrophy Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in HIV-associated Lipodystrophy

Key assessments

- Patient Segmentation in HIV-associated Lipodystrophy

- HIV-associated Lipodystrophy Risk & Burden

- Factors driving growth in a specific HIV-associated Lipodystrophy patient population

HIV-associated Lipodystrophy - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. HIV-associated Lipodystrophy Epidemiology Overview at a Glance
2.1. Patient Share Distribution of HIV-associated Lipodystrophy in 2016
2.2. Patient Share Distribution of HIV-associated Lipodystrophy in 2028
3. Disease Background and Overview: HIV-associated Lipodystrophy
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM
4.3. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM - By Countries
5. Epidemiology of HIV-associated Lipodystrophy by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.1.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy *
5.1.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.1.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.4.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.4.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.4.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.5.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.5.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.5.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.6.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.6.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.6.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.7.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.7.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.7.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.8.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.8.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.8.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.9.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.9.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.9.5. Diagnosed Cases of the HIV-associated Lipodystrophy
6. Unmet Needs of the HIV-associated Lipodystrophy
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Table 5: Sex- Specific Cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Table 6: Diagnosed Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Table 10: Diagnosed Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Table 12: Sub-Type Specific cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Table 13: Sex- Specific Cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Table 14: Diagnosed Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Table 15: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Table 18: Diagnosed Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Table 22: Diagnosed Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Table 24: Sub-Type Specific cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Table 25: Sex- Specific Cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Table 26: Diagnosed Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Table 30: Diagnosed Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the HIV-associated Lipodystrophy in United States (2016-2028)*
Figure 6: Diagnosed Cases of the HIV-associated Lipodystrophy in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the HIV-associated Lipodystrophy in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the HIV-associated Lipodystrophy in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Figure 12: Sub-Type Specific cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Figure 13: Sex- Specific Cases of the HIV-associated Lipodystrophy in France (2016-2028) *
Figure 14: Diagnosed Cases of the HIV-associated Lipodystrophy in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the HIV-associated Lipodystrophy in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the HIV-associated Lipodystrophy in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the HIV-associated Lipodystrophy in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the HIV-associated Lipodystrophy in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the HIV-associated Lipodystrophy in UK (2016-2028) *
Figure 26: Diagnosed Cases of the HIV-associated Lipodystrophy in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the HIV-associated Lipodystrophy in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the HIV-associated Lipodystrophy in Japan (2016-2028)

  • Global Antiretroviral Therapy Market Research Report 2023
    Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antiretroviral Therapy market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Gilead - F. Hoffmann-La Roche - ViiV Healthcare - Boehringer Ingelheim - Janssen Pharmaceuticals - Mylan - Abbvie - Bionor Pharma......
  • Global Antiretroviral Therapy Professional Survey Report 2023, Forecast to 2028
    Published: 22-Mar-2023        Price: US 3280 Onwards        Pages: 108
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Antiretroviral Therapy Market Research Report 2023, Forecast to 2028
    Published: 22-Mar-2023        Price: US 2680 Onwards        Pages: 131
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Antiretroviral Therapy Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
    Published: 21-Sep-2022        Price: US 5600 Onwards        Pages: 104
    Report Scope This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Antiretroviral Therapy manufacturers, distributors, end users, industry associations, governments' industry bureaus, indust......
  • Global Antiretroviral Therapy Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
    Published: 31-Jul-2022        Price: US 3480 Onwards        Pages: 96
    The Antiretroviral Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. According to our (Global I......
  • Global Antiretroviral Therapy Market Insights and Forecast to 2028
    Published: 07-Apr-2022        Price: US 4900 Onwards        Pages: 89
    Antiretroviral Therapy market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Antiretroviral Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - NNRTIs - NRTI - Multiclass Combination Products - Integrase Inhibitors ......
  • United States Antiretroviral Therapy Market Report & Forecast 2021-2027
    Published: 25-Nov-2021        Price: US 3400 Onwards        Pages: 93
    United States Antiretroviral Therapy Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (KG) United States Antiretroviral Therapy Market Segment Percentages, By Type, 2020 (%) - NNRTIs - NRTI - Multiclass Combination Products - Integrase Inhibitors United States Antiretroviral Therapy Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (KG) United States Antiretroviral Therapy Market Segment Percentages, By Application, 2020 (%)......
  • China Antiretroviral Therapy Market Report & Forecast 2021-2027
    Published: 03-Nov-2021        Price: US 3400 Onwards        Pages: 91
    China Antiretroviral Therapy Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (KG) China Antiretroviral Therapy Market Segment Percentages, By Type, 2020 (%) - NNRTIs - NRTI - Multiclass Combination Products - Integrase Inhibitors China Antiretroviral Therapy Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (KG) China Antiretroviral Therapy Market Segment Percentages, By Application, 2020 (%) - Hospital - Clini......
  • Global and United States Antiretroviral Therapy Market Insights, Forecast to 2027
    Published: 12-Aug-2021        Price: US 3900 Onwards        Pages: 130
    Antiretroviral Therapy market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Antiretroviral Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For United States market, this report focuses on the Ant......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs